Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate- to high-risk prostate cancer
British Journal of Radiology · 2024
DOI: 10.1093/bjr/tqae021 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, 2024. Verfasst von Ismail Ali und 6 weiteren Autor:innen. Beteiligte Einrichtung: Radiology Department, Faculty of Human Medicine, Zagazig University, Zagazig, Faculty of medicine street, Zagazig, Sharkia, 44519, Egypt. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Oligopeptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
To assess the utility of 18F-PSMA-1007 PET/MRI in initial staging of intermediate- to high-risk prostate cancer (HRPCa).
Methods
A total of 46 patients with pathologically verified intermediate and/or HRPCa who underwent 18F-PSMA-1007 PET/MRI with dedicated pelvic high-resolution multiparametric MRI (mpMRI) were included.
Results
PET/MRI showed 100% sensitivity (SN), specificity (SP), positive predictive value (PPV), negative predictive value (NPV), and accuracy in detecting seminal vesicle (SV) and rectal invasion, versus 87.5%, 100%, 100% 93.8%, 95.7% and 50%, 100%,100%, 95.5%, and 95.7% for mpMRI respectively. However, PET/MRI had poor SN (40% and 0%) but high SP (94.4% and 100%) in detection of UB and neurovascular bundle (NV) invasion compared to 100% SN and SP for mpMRI. PET/MRI demonstrated stronger TNM staging agreement with the gold standard than mpMRI-WBMRI. It demonstrated concordance with T, N, and M stages in 40, 41, and 36 patients (k 0.84, 0.60, and 0.68, respectively) versus 29, 33, and 31 patients (k 0.54, 0.22, and 0.50) with accurate over all staging of 38/46 patients versus 30/46 patients (K 0.52 versus 0.22).
Conclusion
18F-PSMA-1007 PET/MRI is a promising imaging modality with high diagnostic accuracy in staging intermediate- and HRPCa; it improves local tumour evaluation and provides precise TNM staging. Advances in knowledge 18F-PSMA-1007 PET/MRI could have high diagnostic accuracy as shown in the current study for staging HRPCa patients that is crucial for treatment selection. We think that our study will contribute to the body of knowledge and improve the literature surrounding the clinical uses of integrated 18F-PSMA-1007 PET/MRI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Radiology Department, Faculty of Human Medicine, Zagazig University, Zagazig, Faculty of medicine street, Zagazig, Sharkia, 44519, Egypt.
- Radiology Department, National cancer Institute, Cairo University, Cairo, 11796, Egypt.
- Medical Oncology Department, Faculty of Human Medicine, Zagazig University, Zagazig, 44519, Egypt.
- Radiation Oncology Department, National Cancer Institute, Cairo University, Cairo, 11796, Egypt.
- Director of PET/MRI unit, Misr Radiology Cente, Cairo, 11766, Egypt.
- Radiology Department, Faculty of Human Medicine, Alazhar University, Cairo, 11651, Egypt.
ORCID-Profile: Ismail Ali
Zitieren
APA
Ali, I., Rezk, M., Hamouda, D., Talaat, O., Omar, Y., Abdel Tawab, M., & Nasr, I. (2024). Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate- to high-risk prostate cancer. British Journal of Radiology. https://doi.org/10.1093/bjr/tqae021
Vancouver
Ali I, Rezk M, Hamouda D, Talaat O, Omar Y, Abdel Tawab M, et al. Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate- to high-risk prostate cancer. British Journal of Radiology. 2024. doi:10.1093/bjr/tqae021
BibTeX
@article{Ali2024,
author = {Ali, Ismail and Rezk, Mahmoud and Hamouda, Dalia and Talaat, Omnia and Omar, Yehia and Abdel Tawab, Mohamed and Nasr, Ibrahim},
title = {Clinical value of 18F-PSMA-1007 PET/MRI in primary staging of patients with intermediate- to high-risk prostate cancer},
journal = {British Journal of Radiology},
year = {2024},
doi = {10.1093/bjr/tqae021}
}
EUVIMED